The disclosure relates generally to polyglutamated alpha tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the polyglutamated alpha tetrahydrofolate, and methods of making and using the polyglutamated alpha tetrahydrofolate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis). The disclosed compositions also have uses in combination therapy with one or more therapeutic agents to enhance the effectiveness or to reduce the toxicities associated with the therapeutic agent(s).

Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.

A fusogenic liposome comprising a detectable agent and optionally a cytotoxic drug in its internal aqueous compartment or bound to the liposome membrane is provided, wherein said fusogenic liposome comprises a lipid bilayer comprising a plurality of lipid molecules having 14 to 24 carbon atoms, and at least one of said lipid molecules further comprises a cationic group, a cationic natural or synthetic polymer, a cationic amino sugar, a cationic polyamino acid or an amphiphilic cancer-cell binding peptide; and at least one of said lipid molecules further comprises a stabilizing moiety selected from the group consisting of polyethylene glycol (PEG), polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone (PVP), dextran, a polyamino acid, methyl-polyoxazoline, polyglycerol, poly(acryloyl morpholine), and polyacrylamide. Methods utilizing these liposomes in treatment of cancer are further provided.

The present invention relates to a drug delivery system at least comprising a drug encapsulated in a polymeric nano vesicle (polymersome), wherein the drug component is an anthracycline derivative according to the formula I wherein R.sup.1 is selected from the group consisting of H, F, —OMe or —OEt; R.sup.2 is selected from the group consisting of H, —OMe, methyl or ethyl; R.sup.3 is selected from the group consisting of H, methyl or ethyl, and R.sup.4 is H or a protecting group; the polymersome is formed by polymers comprising PEG, PEA, PCL, PTMC or PTMB building blocks or combinations thereof, wherein the polymersome polymers are, at least in part, functionalized by chemically attaching via a linker group L a targeting moiety, wherein the targeting moiety is selected from the group consisting of antibodies, peptides, aptamers or mixtures thereof. In addition, the present invention relates to process for the production of an anthracycline derivative loaded, targeted polymersome drug delivery system, a pharmaceutical composition comprising said drug delivery system and the use of said pharmaceutical composition for the treatment of cancer.

A method of promoting angiogenesis and cell proliferation in a subject in need of tissue repair and/or regenerative therapy involves administering to the subject a pharmaceutical composition in the form of a hydrogel that includes orange-derived extracellular vesicles (EVs) having a diameter ranging from 10 to 500 nm and showing pro-angiogenic activity. The orange-derived EVs are dispersed in a hydrogel matrix and are releasable from the hydrogel matrix. A method for preparing the pharmaceutical composition in the form of a hydrogel is also provided.

A telodendrimer-nanolipoprotein particle (t-NLP), comprising one or more membrane forming lipids, one or more telodendrimers, and a scaffold protein and a Chlamydia major outer membrane protein (MOMP) comprising a MOMP hydrophobic region, and related compositions methods and systems.

The present invention is directed to a nanoparticle or microparticle for binding to the surface of a cell, wherein the nanoparticle or microparticle comprises (i) multiple different ligand types on its external surface which are capable of binding to different respective receptor types on said cell surface, and (ii) a polymer brush on its external surface. The present invention is further directed to pharmaceutical compositions comprising a plurality of nanoparticles or microparticles of the invention, medical uses of such nanoparticles or microparticles, and a vaccine comprising such nanoparticles or microparticles.

This disclosure provides compositions and methods for stimulating the innate immune response in a subject with agents capable of stimulating an innate immune response in a subject upon administration to the subject (e.g., damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)). In particular, the present invention is directed to compositions of DAMPs/PAMPs and metals ions, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).

The present invention relates to lipid-coated particles for treating viral infections, including viral encephalitis infections. In particular, an antiviral compound can be disposed within the lipid-coated particle, thereby providing an antiviral carrier. Methods of making and using such carriers are described herein.

A monomeric bispecific polyethylene glycol (PEG) engager that includes an anti-PEG Fab fused to a disulfide stabilized scFv that specifically binds to a cell surface antigen. The PEG engager, in the absence of PEG, remains monomeric upon binding to the cell surface antigen on a cell and remains on the surface of the cell. Also disclosed is a method for treating cancer by administering a PEG engager followed by a PEGylated anti-cancer agent. Further disclosed is a method for diagnosing a cell-mediated disorder by administering a PEG engager followed by a PEGylated diagnostic agent.